Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urgency-Frequency Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

NCT05308979
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge, Urge Incontinence, Urinary Urgency, Urinary Frequency
Interventions
OnabotulinumtoxinA 100 UNT [Botox]
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 29, 2026, 11:18 AM EDT
Terminated Phase 4 Interventional Results available

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

NCT01302938
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tolterodine ER, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 29, 2026, 11:18 AM EDT
Terminated Phase 2 Interventional

Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

NCT00332319
View directory record Official record
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Long Beach, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 29, 2026, 11:18 AM EDT
Not listed Phase 3 Interventional

Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms

NCT00094874
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Acupuncture
Procedure
Lead sponsor
The Mary Elizabeth Groff Surgical Medical Research and Education Charitable Trust
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 29, 2026, 11:18 AM EDT
Completed Phase 4 Interventional

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

NCT00147654
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
95
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 29, 2026, 11:18 AM EDT
Not yet recruiting Phase 4 Interventional

Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

NCT06695585
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
Interventions
Lidocaine 2% without vessel constrictor
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 29, 2026, 11:18 AM EDT
Terminated Phase 4 Interventional Results available

OnabotulinumtoxinA Bladder Injection Study

NCT03523091
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Incontinence, Urinary Frequency/Urgency, Urinary Bladder, Overactive
Interventions
OnabotulinumtoxinA 100Unit Injection
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Sep 29, 2026, 11:18 AM EDT
Not listed Phase 4 Interventional

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

NCT00826527
View directory record Official record
Conditions
Urinary Frequency, Urinary Urgency, Nocturia
Interventions
Solifenacin PO
Drug
Lead sponsor
Seattle Urology Research Center
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Sep 29, 2026, 11:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sensory Sensitivity and Urinary Symptoms in the Female Population

NCT01978002
View directory record Official record
Conditions
Bladder Pain and Discomfort, Urinary Urgency and Frequency, Bothersome Symptoms
Interventions
Pain sensitivity testing, Urodynamic testing
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Sep 29, 2026, 11:18 AM EDT
Terminated Not applicable Interventional

The Effects of Sacral Neuromodulation for Urinary Urgency, Frequency, and Urge Incontinence

NCT02776475
View directory record Official record
Conditions
Urinary Urge Incontinence
Interventions
Sacral neuromodulation device turned off
Procedure
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 29, 2026, 11:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

NCT00911235
View directory record Official record
Conditions
Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
Interventions
Fesoterodine, fesoterodine plus fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2011 · Synced Sep 29, 2026, 11:18 AM EDT
Terminated Not applicable Interventional

Pelvic Floor Muscle Training With Leva System for Urge Incontinence

NCT03923348
View directory record Official record
Conditions
Overactive Bladder, Urge Urinary Incontinence, Mixed Urinary Incontinence
Interventions
Leva device
Device
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 29, 2026, 11:18 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Development of Novel Cystometrics for Overactive Bladder

NCT02060214
View directory record Official record
Conditions
Urinary Frequency/Urgency
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
22 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 29, 2026, 11:18 AM EDT
Completed Early Phase 1 Interventional

Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder

NCT05463822
View directory record Official record
Conditions
Overactive Bladder, Bladder, Overactive, Urge Incontinence, Urgency Urinary, Urinary Frequency/Urgency
Interventions
Transvaginal botulinum toxin A (BTA) injection
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 29, 2026, 11:18 AM EDT
Withdrawn Not applicable Interventional

INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder

NCT05309993
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urge Incontinence, Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions
PTNS, TENS
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 29, 2026, 11:18 AM EDT
Completed Phase 4 Interventional

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

NCT00333112
View directory record Official record
Conditions
Urinary Incontinence
Interventions
solifenacin succinate, tamsulosin, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 29, 2026, 11:18 AM EDT
Completed Phase 3 Interventional Results available

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
106
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 29, 2026, 11:18 AM EDT
Recruiting Not applicable Interventional

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

NCT06511141
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
Interventions
Axonics SNM System
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 29, 2026, 11:18 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

NCT00295854
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
MN-001 BID, MN-001, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Glendora, California • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Sep 29, 2026, 11:18 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

OAB and the Microbiome

NCT04831801
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 29, 2026, 11:18 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00912964
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
82
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 29, 2026, 11:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Linkage Analysis in Interstitial Cystitis

NCT00675298
View directory record Official record
Conditions
Prostatitis, Cystitis, Interstitial, Urinary Bladder, Overactive, Chronic Pelvic Pain Syndrome, Painful Bladder Syndrome
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
3 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 29, 2026, 11:18 AM EDT
Recruiting Not applicable Interventional

Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement

NCT04527445
View directory record Official record
Conditions
Radiation Exposure, Overactive Bladder, Urge Incontinence, Urgency-frequency Syndrome
Interventions
Reduced radiation fluoroscopy, Conventional fluoroscopy
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 89 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 29, 2026, 11:18 AM EDT
Completed Not applicable Interventional

rTMS in Overactive Bladder

NCT06198439
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urgency-frequency Syndrome, Urinary Incontinence, Urinary Incontinence, Urge
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 29, 2026, 11:18 AM EDT